Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab).
Verona Pharma said that the first part of a two-part phase 2 trial of ensifentrine in a dry powder inhaler (DPI) formulation for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) has yielded positive interim efficacy and safety data.
Shield Therapeutics said that its oral ferric iron therapy Feraccru proved to be non-inferior to Ferinject (ferric carboxymaltose or FCM), a widely used intravenously delivered iron replacement therapy, in the AEGIS-H2H non-inferiority study.
Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).
A clinical trial held in the UK in patients with Parkinson’s Disease showed that it could be possible to restore damaged neurons by boosting the levels of a naturally-occurring protein called Glial Cell Line Derived Neurotrophic Factor (GDNF).
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence human pharmacokinetics studies for the Company's lead asset NXP001.
The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.
Amgen, Cytokinetics, and Servier announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
Sosei Group announced that the first healthy subject has been dosed with a small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program targeting endocrine disorders, including Cushing’s disease.
Innovent has entered into a collaboration with Shenzhen Chipscreen Biosciences to evaluate a combination therapy made up of their respective drugs in colorectal cancer patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.